Last reviewed · How we verify
Placebo ELLIPTA device
Placebo ELLIPTA device is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Clinical trial control/comparator (not a therapeutic indication).
A placebo device with no active pharmaceutical ingredient, used as a control in clinical trials.
A placebo device with no active pharmaceutical ingredient, used as a control in clinical trials. Used for Clinical trial control/comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo ELLIPTA device |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
The ELLIPTA device is an inhalation delivery platform manufactured by GlaxoSmithKline. When used as a placebo, it delivers no active drug substance, serving as a comparator in randomized controlled trials to assess the efficacy of active medications delivered via the same device platform.
Approved indications
- Clinical trial control/comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma (PHASE4)
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (PHASE2)
- Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery (PHASE3)
- A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. (PHASE2)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma (PHASE3)
- A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo ELLIPTA device CI brief — competitive landscape report
- Placebo ELLIPTA device updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo ELLIPTA device
What is Placebo ELLIPTA device?
How does Placebo ELLIPTA device work?
What is Placebo ELLIPTA device used for?
Who makes Placebo ELLIPTA device?
What development phase is Placebo ELLIPTA device in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Indication: Drugs for Clinical trial control/comparator (not a therapeutic indication)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing